97 filings
Page 3 of 5
8-K
hpve648nvac9
26 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
7kwac3 e3
2 May 23
Other Events
12:00am
8-K
hwlek3ifk5ax xu5ysr
25 Apr 23
Entry into a Material Definitive Agreement
5:00pm
8-K
fkm1j
19 Apr 23
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
4:30pm
8-K
faizugymq7r
12 Apr 23
Entry into a Material Definitive Agreement
5:00pm
8-K
woaj6l bv
11 Apr 23
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
9:19am
8-K
2m0tk4tqk6bpw 2wlo1
28 Mar 23
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
5:15pm
8-K
rwkxyn
24 Mar 23
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
6:08am
8-K
wekefbulwx abnwb
20 Mar 23
Amendments to Articles of Incorporation or Bylaws
5:14pm
8-K
av4yvpl
20 Mar 23
Regulation FD Disclosure
6:05am
8-K
cyh8wuddsg tb9m5gtqj
9 Mar 23
Regulation FD Disclosure
5:10pm
8-K
drlmkkhw39a91s
28 Feb 23
Entry into a Material Definitive Agreement
5:25pm
8-K
hoamaplra4i vizs
10 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
djjvuvxd
6 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:33am
8-K
59e4vp34zjjd3
23 Jan 23
Entry into a Material Definitive Agreement
6:30am
8-K
ypa758
20 Jan 23
Allarity Therapeutics Announces Adjournment of
4:17pm
8-K
o498ptwqir8b8xlz6
19 Jan 23
Entry into a Material Definitive Agreement
4:01pm
8-K
81qzagrh2h3dd ixzwro
18 Jan 23
Other Events
6:03am
8-K
001rrib0ccq5vm ytzwi
23 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:30am
8-K
81nnug3br01f9as
21 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:15am